Retrospective Analysis of Patients With Metastatic Renal Cell Carcinoma Treated With CABOzantinib

Who May Qualify: - Age ≥ 18 years. - Patients with histological diagnosis of predominantly clear cell carcinoma - Availability of the tumor tissue from the primary tumor and/or a metastatic site for the genomic profiling analysis not older than 5 years. - Evaluable disease according to RECIST criteria v 1.1 - Treatment with cabozantinib after one or more previous therapies for mRCC - Patient progressed from the start to cabozantinib therapy within 3 months or after 9 months - Any prognosis group according to the IMDC risk score - Signed willing to sign a consent form must be obtained for living patients. Patients who died and patient untraceable will be analyzed based on the Authorization no. 9/2016 of the Italian Data Protector Supervisor. Who Should NOT Join This Trial: - Non-availability of tumor tissue from the primary tumor or a metastatic site for biomarker analysis - Patient progressed between 3 and 9 months from the beginning of treatment with cabozantinib. - Non-availability of clinical information useful to evaluate the IMDC risk group at baseline. Always talk to your doctor about whether this trial is right for you.